$136.44
2.48% yesterday
Nasdaq, Nov 12, 10:00 pm CET
ISIN
US81663L2007
Symbol
WGS

GeneDx Stock price

$136.44
+15.57 12.88% 1M
+77.44 131.25% 6M
+59.58 77.52% YTD
+59.52 77.38% 1Y
+106.86 361.29% 3Y
-203.46 59.86% 5Y
-186.96 57.81% 10Y
-186.96 57.81% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-3.47 2.48%
ISIN
US81663L2007
Symbol
WGS

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.9b
Net debt
positive
Cash
$155.1m
Shares outstanding
29.0m
Valuation (TTM | estimate)
P/E
2,274.0 | 81.8
P/S
10.0 | 9.4
EV/Sales
9.7 | 9.2
EV/FCF
261.3
P/B
13.7
Financial Health
Equity Ratio
58.5%
Return on Equity
-21.2%
ROCE
2.5%
ROIC
2.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$402.2m | $426.2m
EBITDA
$33.2m | $64.6m
EBIT
$10.0m | $55.9m
Net Income
$2.3m | $49.4m
Free Cash Flow
$15.0m
Growth (TTM | estimate)
Revenue
50.5% | 39.5%
EBITDA
171.9% | 1,312.1%
EBIT
117.3% | 340.6%
Net Income
102.7% | 194.6%
Free Cash Flow
125.1%
Margin (TTM | estimate)
Gross
69.7%
EBITDA
8.3% | 15.2%
EBIT
2.5%
Net
0.6% | 11.6%
Free Cash Flow
3.7%
More
EPS
$0.1
FCF per Share
$0.5
Short interest
24.2%
Employees
1k
Rev per Employee
$310.0k
Show more

Is GeneDx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

GeneDx Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a GeneDx forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a GeneDx forecast:

Buy
85%
Hold
15%

Financial data from GeneDx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
402 402
51% 51%
100%
- Direct Costs 122 122
13% 13%
30%
280 280
76% 76%
70%
- Selling and Administrative Expenses 188 188
23% 23%
47%
- Research and Development Expense 58 58
29% 29%
14%
33 33
172% 172%
8%
- Depreciation and Amortization 23 23
101% 101%
6%
EBIT (Operating Income) EBIT 9.97 9.97
117% 117%
2%
Net Profit 2.27 2.27
103% 103%
1%

In millions USD.

Don't miss a Thing! We will send you all news about GeneDx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,000 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

Head office United States
Employees 1,000
Website sema4.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today